Enantiomeric Separation of A2-73 for Sigma 1 Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and methods for classifying sigma receptor types are limited by the presence of both σ1 and σ2 receptor agonists, which can lead to unintended effects and lack of specificity.
Innovation Solution
A pharmaceutical preparation comprising ⊖A2-73 substantially free of ⊕A2-73 is developed, which is used to administer a therapeutically effective dose for enhanced stimulation of sigma 1 receptors, treatment of Alzheimer's disease, and classification of cells as to sigma receptor type.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If both σ1 and σ2 receptor agonists are used in current treatments, then broader receptor coverage is achieved, but specificity is reduced and unintended effects occur
Solution Approach 1:
The patent segments the racemic A2-73 compound into its individual enantiomeric components (⊖A2-73 and ⊕A2-73). By isolating and characterizing each enantiomer separately, the invention enables selective use of the ⊖A2-73 enantiomer which provides sigma-1 receptor agonist activity with reduced sigma-2 receptor activity, thus achieving both versatility and specificity.
Solution Approach 2:
The patent applies local quality by assigning different functional properties to different enantiomeric forms of the same compound. The ⊖A2-73 enantiomer is identified as having preferential sigma-1 receptor agonist activity, while the ⊕A2-73 enantiomer has different activity profiles. This allows selective application of the appropriate enantiomer based on the desired therapeutic effect and target receptor type.
2Ease of manufacture
If racemic A2-73 is used, then ease of manufacture is maintained, but unintended effects occur due to lack of enantiomeric selectivity
Solution Approach 1:
The patent extracts the harmful component (⊕A2-73 enantiomer) from the racemic mixture, leaving only the beneficial ⊖A2-73 enantiomer. This extraction eliminates the unintended effects associated with the ⊕A2-73 enantiomer while preserving the therapeutic benefits of the ⊖A2-73 enantiomer, and the extracted component can be separately characterized and managed.
3Device complexity
If sigma receptor ligands are used without enantiomeric separation, then treatment complexity is reduced, but measurement precision of receptor binding is compromised
Solution Approach 1:
The patent performs preliminary action by conducting enantiomeric separation and characterization before the actual therapeutic application. By预先 separating the racemic mixture into individual enantiomers and determining their specific receptor binding properties, the invention enables more precise and accurate measurement of sigma receptor binding in subsequent applications, while the separated enantiomers can be stored and applied as needed.
Data Source
AI summary
A pharmaceutical preparation comprising ⊖A2-73 substantially free of ⊕A2-73. This invention further includes a method treating Alzeheimer's disease in a subject in need of such treatment by the method of administering a therapeutically effective amount of ⊖A2-73 substantially free of ⊕A2-73. This invention yet further includes a method of classifying cells as to sigma receptor type by the method of exposing said cells to a detectable amount of ⊖A2-73 substantially free of ⊕A2-73 and determining the level of sigma receptor binding.